Low-dose zinc therapy for maintenance treatment of Wilson's disease.
Mayet
I Y
IY
Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
D000284:Administration, Oral; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003300:Copper / Q000097:blood / Q000378:metabolism / Q000652:urine; D006527:Hepatolenticular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000009:adverse effects; D013431:Sulfates / Q000008:administration & dosage / Q000627:therapeutic use*; D015032:Zinc / Q000008:administration & dosage / Q000627:therapeutic use*; D019287:Zinc Sulfate
D013431:Sulfates; D019287:Zinc Sulfate; D003300:Copper; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010396:Penicillamine; D015032:Zinc